Phase 1/2 AQUAx Clinical Trial

We are currently conducting the AQUAx clinical study to evaluate the safety of our investigational gene therapy AAV-AQP1 and its potential to relieve symptoms of xerostomia. This multi-site Phase 1/2 clinical trial is enrolling participants who have been diagnosed with grade 2 or 3 radiation-induced xerostomia (RIX) and who have remained cancer free for at least five years (or two years if HPV+) after receiving radiation treatment for head and neck cancer.

 

Find more information about the clinical trial at www.aquaxstudy.com or visit clinicaltrials.gov.